Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Diagnostic or test agent produces visible change on skin
Reexamination Certificate
2011-08-02
2011-08-02
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Diagnostic or test agent produces visible change on skin
C424S093700, C424S093710, C435S002000, C604S004010, C604S006030, C604S006080
Reexamination Certificate
active
07988951
ABSTRACT:
Transimmunization methods incorporating skin immunologic challenges are described for either selectively suppressing the immune response of recipients of transplanted tissue or cells or monitoring induced anti-cancer immunity. In one embodiment, skin from the transplant donor is allografted to the transplant recipient to induce an immunological response to the transplanted skin. A quantity of blood is taken from the recipient and treated to render the T cells in the blood apoptotic and to induce differentiation of blood monocytes into dendritic cells. The treated blood is incubated and administered to the recipient to induce formation of suppressor T cell clones which reduce the number of T cells attacking the transplanted tissue or organ. This tolerogenic approach can be complemented by also feeding the immature dendritic cells apoptotic or necrotic cells from the organ donor. In a second embodiment, dendritic cells loaded with tumor antigens are injected intradermally to monitor the anti-cancer immunity induced by Transimmunization.
REFERENCES:
patent: 4321918 (1982-03-01), Clark, II
patent: 4683889 (1987-08-01), Edelson
patent: 4838852 (1989-06-01), Edelson et al.
patent: 6194204 (2001-02-01), Crawford et al.
patent: 6524855 (2003-02-01), Edelson et al.
patent: 6596275 (2003-07-01), Bartholeyns et al.
patent: 6602709 (2003-08-01), Albert et al.
patent: 6800300 (2004-10-01), Miller et al.
patent: 2002/0051771 (2002-05-01), Bolton et al.
patent: 2002/0114793 (2002-08-01), Edelson et al.
patent: 2003/0133914 (2003-07-01), Edelson et al.
patent: 2005/0084966 (2005-04-01), Edelson et al.
patent: 97/34472 (1997-09-01), None
patent: 00/62818 (2000-10-01), None
Greinix, et al. Successful Use of Extracorporeal Photochemotherapy in the Treatment of Severe Acute and Chronic Graft-Versus-Host Disease, Blood, vol. 92, No. 9, 1998, pp. 3098-3104.
Greinix, et al. Extracorporeal Photochemotherapy in the Treatment of Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Pilot Study, Blood, vol. 96, No. 7,, 2000, pp. 2426-2431.
Ullrich, Photoinactivation of T-cell function with psoralen and UVA radiation suppresses the induction of experimenta; murine graft-versus-host disease across major histocompatibility barriers: Jour. Invest. Dermatol., vol. 96, No. 3, 1991, pp. 303-308.
Cohen, et al. CD4+CD25+ Immunoregulatory T Cells: New Therapeutics for Graft-Versus-Host Disease, The Rockefeller University Press, vol. 196, No. 3, Aug. 5, 2002, pp. 401-406.
Chambers, The expanding world of co-stimulation: the two-signal model revised, Trends in Immunology, vol. 22, No. 4, Apr. 2001, pp. 217-223.
Hoffmann, et al. Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation, The Rockefeller University Press, vol. 196, No. 3, Aug. 5, 2002, pp. 389-399.
Rossi, M. et al., Plasmacytoid Dendritic Cells: Do They Have a Role in Immune Responses After Hematopoietic Cell Transplantation? Human Immunology Dec. 2002, vol. 63, No. 12, pp. 1194-1200.
Heshmati, F. Mechanisms of Action of Extracorporeal Photochemotherapy Transfusion and Apheresis Science Aug. 2003, vol. 29, No. 1, pp. 61-70, Abstract.
Ying G et al: “Tricyclic antidepressants prevent the differentiation of monocytes into macrophage-like cells in vitro.” Cel Biol Toxicol 2002; 18(6):425-37.
Beaudoin L et al: “NKT cells inhibit the onset of diabetes by impairing the development of pathogenic T cells specific for pancreatic beta cells.” Immunity. Dec. 2002; 17(6):725-36.
Kitazawa T et al: “Studies on delayed systemic effects of ultraviolet B radiation on the induction of contact hypersensitivity, 3. Dendritic cells from secondary lymphoid organs are deficient in interleukin-12 production and capacity to promote activation and differentiation of T helper type 1 cells.” Immunology. Feb. 2000;99(2):296-304.
Tang A et al: “Inhibition of epidermal Langerhans cell function by law dose ultraviolet B radiation. Ultraviolet B radiation selectively modulates ICAM-1 (CD54) expression by murine Langerhans cells.” J Immunol. May 15, 1991;146(10):3347-55.
Shen W et al: “Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells.” Cell Immunol. Dec. 2002;220(2):125-33.
Lateef Z et al: “Orf virus-encoded interleukin-10 inhibits maturation, antigen presentation and migration of murine dendritic cells.” J Gen Virol. May 2003;84(Pt5): 1101-0.
Shurin MR et al: “Inhibition of CD40 expression and CD-40-mediated dentritic dell function by tumor-derived IL-10.” Int J Cancer. Sep. 1, 2002;101(1):61-8.
Semnani RT et al: “Filarial antigens impair the function of human dendritic cells during differentiation.” Infect Immun. Sep. 2001;69(9):5313-22.
Chung F: “Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma.” Mediators Inflamm. Apr. 2001;10(2):51-9. Links.
Hackstein H et al: “Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dentritic cells.” J Immunol. Jun. 15, 2001;166(12):7053-62.
Komi J et al: “Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells.” Rheumatology (Oxford). Feb. 2001;40(2):185-91.
Moore KW et al: “Interleukin-10 and the interleukin-10 receptor.” Annu Rev Immunol. 2001;19:683-785.
Bernstein SH et al: “A randomized phase II study of BB-10010: a variant of human macrophage inflammatory protein-1 alpha for patients receiving high-dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer.” BR J Haematol. Dec. 1997;99(4):888-95.
Askenase PW et al: “Gamma delta T cells in normal spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity. Effect of Bordetella pertussis, cyclophosphamide, and antibodies to determinants on suppressor cells.” J Immunol. Apr. 15, 1995;154(8):3644-53.
De Smedt T et al: “Effect of interleukin-10 on dendritic cell maturation and function.” Eur J Immunol. May 1997;27(5):1229-35.
Hirohata S: “Suppression of human B cell responsiveness by CD4+ T cells does not involve CD95-CD95 ligand interactions.” Cell Immunol. Nov. 1, 1997;181(2):182-91.
Estry DW et al: “A comparison of the fibrinogen receptor distribution on adherent platelets using bath soluble fibrinogen and fibrinogen immobilized on gold beads.” Eur J Cell Biol. Apr. 1991;54(2):196-210.
Blank K et al: “Self-immobilizing recombinant antibody fragments for immunoaffinity chromatography: generic, parallel, and scalable protein purification.” Protein Expr Purif. Mar. 2002:24(2):313-22.
Garlie NK et al: “T cells activated in vitro as immunotherapy for renal cell carcinoma: characterization of 2 effector T-cell populations.” J Urol. Jul. 2001;166(1):299-303.
Foger N et al: “CD44 supports T cell proliferation and apoptosis by apposition of protein kinases.” Eur J Immunol Oct. 2000;30(10):2888-99.
Hanau D et al: “A method for the rapid isolation of human epidermal Langerhans cells using immunomagnetic microspheres.” J Invest Dermatol. Sep. 1988;91(3):274-9.
Thomas R et al: “Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells.” J. Immunol. Nov. 1, 1994;153(9):4016-28.
Yanagihara S et al: “EBI1/CCR7 Is a New Member of Dendritic Cell Chemokine Receptor That is Up-Regulated Upon Maturation.” The Journal of Immunology 1998, 161: 3096-3102.
Li B et al: “Pretreatment of recipients with mitomycin-C-treated dendritic cells induces significant prolongation of cardiac allograft survival in mice.” Transplantation Proceedings vol. 34, Issue 8, Dec. 2002, pp. 3426-3428.
Hawiger D et al: “Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions in Vivo,” The Journ
McCarter & English LLP
Saunders David A
Yale University
LandOfFree
Method for inducing selectively suppressed immune response... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inducing selectively suppressed immune response..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inducing selectively suppressed immune response... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791212